Stratec SE

XETRA SBS.DE

Stratec SE Price to Earnings Ratio (P/E) on January 14, 2025: 24.54

Stratec SE Price to Earnings Ratio (P/E) is 24.54 on January 14, 2025, a -41.43% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Stratec SE 52-week high Price to Earnings Ratio (P/E) is 47.53 on June 03, 2024, which is 93.67% above the current Price to Earnings Ratio (P/E).
Stratec SE 52-week low Price to Earnings Ratio (P/E) is 23.65 on December 09, 2024, which is -3.64% below the current Price to Earnings Ratio (P/E).
Stratec SE average Price to Earnings Ratio (P/E) for the last 52 weeks is 39.45.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

XETRA: SBS.DE

Stratec SE

CEO	Mr. Marcus Wolfinger
IPO Date	June 16, 2000
Location	Germany
Headquarters	Gewerbestrasse 37
Employees	1,462
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

Key trends

Past 5 years